North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
|Articles|May 16, 2012
Surya Singh, MD, Addresses Ways to Manage Oncology Spending in Specialty Pharmacy
Dr. Singh discusses CVS Caremark's strategies for managing oncology spending.
Advertisement
Surya Singh, MD, Vice President, Medical Benefit Management, CVS Caremark, states that there are a variety of approaches used to stem the rise of costs associated with oncology. However, Dr. Singh point out that there is not a one-size-fits-all approach to doing so.
Advertisement
Related to this article
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
The FDA has approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatments for those with disease progression.
Advertisement
Advertisement